European Notebook: Agreements On Sovaldi, Olysio Pricing; Drug Shortages Increase; Rawlins Returns As Regulator
Executive Summary
Patient access to the new generation of hepatitis C therapies is set to improve in Europe as pricing negotiations conclude, but concerns increase that a number of other marketed drugs are suffering supply shortages.
You may also be interested in...
Drug Makers Relieved As Europe's Unitary Patent Gets Predictable Boost
The Advocate General of the Court of Justice of the European Union has dismissed Spain’s second challenge to the unitary patent, offering more legal certainty for drug manufacturers and pointing the way towards reduced litigation costs.
EU/U.S. Trade Pact Talks May Stumble Over Drug Regulation, Affordability
The EU Parliament’s health committee has highlighted regulatory pitfalls within TTIP, while civil society elements decry its lack of transparency and potential impact on health care affordability.
Market Snapshot: Diabetic Macular Edema, Another Blockbuster Opportunity For Retinal Drugs?
Having relatively rapidly built a multi-billion dollar market in wet age-related macular degeneration, biotech and pharma companies may be about to repeat the exercise with diabetic macular edema, a complication of diabetes that’s growing in importance as the population ages and the disease spreads.